| Gene symbol | MUC1 | Synonyms | ADMCKD, ADMCKD1, ADTKD2, CA 15-3, CD227, Ca15-3, EMA, H23AG, KL-6, MAM6, MCD, MCKD, MCKD1, MUC-1, MUC-1/SEC, MUC-1/X, MUC1/ZD, PEM, PEMT, PUM | Type of gene | protein-coding |
| Chromosome | 1 | Map location | 1q22 | dbXrefs | |
| Gene perturbation-related omics dataset | PerturbAtlas | ||||
| Description | mucin 1, cell surface associated | ||||
| GTO ID | GTC2931 |
| Trial ID | NCT05239143 |
| Disease | Colorectal Cancer | Nasopharyngeal Cancer | Stomach Cancer | Renal Cell Carcinoma | Pancreatic Cancer | Head and Neck Squamous Cell Carcinoma | Lung Non-Small Cell Carcinoma | Ovarian Cancer | Breast Cancer |
| Altered gene | MUC1 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | P-MUC1C-ALLO1 |
| Phase | Phase1 |
| Recruitment status | Recruiting |
| Title | P-MUC1C-ALLO1 Allogeneic CAR-T Cells in the Treatment of Subjects With Advanced or Metastatic Solid Tumors |
| Year | 2022 |
| Country | United States |
| Company sponsor | Poseida Therapeutics, Inc. |
| Other ID(s) | P-MUC1C-ALLO1-001 |
| Cohort 1 | |||||||||
|
|||||||||